

# USE OF NON-INVASIVE RESPIRATORY SUPPORT IN PREMATURE INFANTS: CURRENT PRACTICES, CHALLENGES, AND FUTURE DIRECTIONS

Rustamov Bakhtiyorjon Bobokulovich

Bukhara State Medical Institute, Assistant of the II- Pediatrics Department

## Abstract

Premature birth often results in significant respiratory challenges due to structural lung immaturity and surfactant deficiency, making respiratory support critical in neonatal intensive care. Traditionally, invasive mechanical ventilation was used, but its association with ventilator-induced lung injury (VILI), bronchopulmonary dysplasia (BPD), and long-term neurodevelopmental impairment led to a shift toward non-invasive respiratory support (NIRS). Techniques such as continuous positive airway pressure (CPAP), high-flow nasal cannula (HFNC), nasal intermittent positive pressure ventilation (NIPPV), and bi-level positive airway pressure (BiPAP) now play essential roles in neonatal respiratory care. This article provides an in-depth review of the physiological rationale, modalities, clinical evidence, emerging technologies, implementation challenges, and the future of non-invasive support in the care of premature neonates. Emphasis is placed on current global practices, innovations like less invasive surfactant administration (LISA), and the integration of artificial intelligence and personalized care in neonatal intensive care units (NICUs).

**Keywords:** Respiratory distress syndrome (RDS), bronchopulmonary dysplasia (BPD), very low birth weight (VLBW), non-invasive respiratory support (NIRS), CPAP, HFNC, NIPPV, BiPAP, LISA, neonatal outcomes, neonatal intensive care, artificial intelligence in NICU, neonatal neurodevelopment, global neonatal health.

## Introduction

Premature infants, especially those born before 32 weeks of gestation, commonly suffer from underdeveloped lungs and insufficient surfactant production, leading to respiratory distress syndrome (RDS). As the survival of extremely preterm infants improves due to advancements in neonatal care, the focus has shifted to minimizing iatrogenic injury and enhancing long-term outcomes. Invasive mechanical ventilation, while lifesaving, is associated with adverse effects such as BPD, pulmonary interstitial emphysema, and neurodevelopmental delay [1,4].

Non-invasive respiratory support (NIRS) techniques aim to stabilize gas exchange while avoiding intubation-related trauma and lung injury. Their introduction marks a pivotal shift toward lung-protective ventilation strategies in neonatal care [2,3].

**1. Pathophysiology and Rationale for Non-Invasive Support.** The preterm lung is susceptible to structural damage due to high alveolar surface tension, surfactant deficiency, and an



underdeveloped antioxidant defense system. Invasive ventilation can exacerbate lung injury through mechanisms such as:

- **Barotrauma:** Injury from high airway pressures.
- **Volutrauma:** Damage from excessive tidal volumes.
- **Atelectrauma:** Repetitive opening and closing of alveoli.
- **Biotrauma:** Inflammatory cytokine release leading to systemic effects[5].

NIRS modalities provide continuous or intermittent distending pressure, helping maintain alveolar patency, optimize ventilation-perfusion matching, and preserve spontaneous respiratory efforts, all while minimizing systemic inflammation[6].

### 3. Modalities of Non-Invasive Respiratory Support

**3.1 Continuous Positive Airway Pressure (CPAP).** CPAP remains the cornerstone of NIRS and is used in both the delivery room and NICU. It delivers a constant positive pressure to prevent alveolar collapse, improve oxygenation, and reduce work of breathing. Nasal interfaces such as prongs and masks are used to deliver CPAP. Evidence supports early CPAP initiation (in the delivery room) as it significantly lowers the need for intubation and surfactant[7].

**3.2 High-Flow Nasal Cannula (HFNC).** HFNC is favored for its simplicity and comfort. It delivers heated and humidified gases at flow rates typically between 2–8 L/min in neonates, which generate positive airway pressure and reduce dead space. While widely used post-extubation or as step-down therapy, HFNC may not be as effective as CPAP in very low birth weight (VLBW) or extremely low gestational age infants (<28 weeks)[8].

**3.3 Nasal Intermittent Positive Pressure Ventilation (NIPPV).** NIPPV provides CPAP with superimposed ventilator breaths, either synchronized or unsynchronized. It enhances minute ventilation, supports tidal volume, and reduces apnea of prematurity. Synchronization (sNIPPV) further improves efficacy and may reduce the incidence of extubation failure[9,10].

**3.4 Bi-level Positive Airway Pressure (BiPAP).** BiPAP cycles between two positive pressure levels, supporting gas exchange and reducing respiratory effort. Its role remains under investigation but may be beneficial in select populations with evolving respiratory failure or post-extubation.

**4. Evidence-Based Practices and Guidelines.** Numerous randomized controlled trials (RCTs) and meta-analyses have shaped current NIRS strategies:

- **SUPPORT Trial (2010):** Demonstrated that early CPAP was non-inferior to early intubation with surfactant in infants 24–27 weeks gestation and led to fewer complications.
- **COIN Trial (2008):** Found increased risk of pneumothorax with early CPAP but reduced need for mechanical ventilation.
- **European Consensus Guidelines (2022):** Recommends early CPAP in all spontaneously breathing preterm infants and cautions against routine primary use of HFNC in those <28 weeks.



Global implementation of these guidelines has significantly improved neonatal outcomes, though access and adherence vary by region.

## 5. Clinical Benefits of NIRS

- **Reduced incidence of BPD** due to avoidance of intubation and mechanical ventilation.
- **Preservation of upper airway defense mechanisms** reducing nosocomial infection risk.
- **Enhanced comfort and bonding**, allowing earlier initiation of skin-to-skin contact and breastfeeding.
- **Decreased sedation requirements**, improving feeding tolerance and neurodevelopment.
- **Shorter hospital stays** in many cases due to fewer complications.

## 6. Limitations and Practical Challenges

- **CPAP Failure:** Up to 40% of infants may eventually require mechanical ventilation, especially those with severe surfactant deficiency.
- **Nasal trauma:** Extended use can cause septal injury, requiring skilled nursing care and frequent monitoring.
- **Variability in equipment and protocols:** Discrepancies between high-income and low-resource settings in NIRS availability and practice.
- **Monitoring challenges:** Difficulty in assessing work of breathing and synchrony without advanced tools.

## 7. Technological and Therapeutic Innovations

**7.1 Less Invasive Surfactant Administration (LISA).** LISA involves delivering surfactant via a thin catheter during spontaneous breathing supported by CPAP. This technique avoids intubation and has been shown to reduce BPD rates in several European and Asian cohorts.

**7.2 Artificial Intelligence and Smart NICUs.** AI-driven monitoring systems and wearable sensors now allow real-time adjustments to respiratory support, predict respiratory deterioration, and alert clinicians before clinical signs appear. Such personalized interventions are improving outcomes and reducing alarm fatigue.

**7.3 Telemedicine in Neonatal Care.** In low-resource settings, telemedicine and portable CPAP/HFNC devices enable remote neonatal respiratory support. Programs such as Helping Babies Breathe and UNICEF's neonatal care platforms are extending NIRS globally.

**7.4 Biomarkers and Genomics.** Emerging studies are exploring surfactant protein levels (SP-A, SP-B, SP-D) and genetic markers of BPD to guide NIRS selection and predict therapy response.

**8. Global and Ethical Considerations.** While high-income countries report high survival rates with NIRS, implementation in low- and middle-income countries (LMICs) is challenged by cost, lack of equipment, and training gaps. WHO advocates for scalable NIRS solutions, including



bubble CPAP systems and simplified HFNC devices. Ethical dilemmas arise in cases with borderline viability, requiring shared decision-making and family counseling.

**9. Future Directions. Standardization of NIRS protocols** across NICUs for consistency and quality assurance.

- **Wider implementation of LISA** combined with CPAP.
- **Global health initiatives** to provide affordable, robust respiratory support in LMICs.
- **Further trials** on synchronized NIPPV and early HFNC use.
- **Integration of AI** into neonatal monitors and ventilators for real-time, data-driven interventions.

## 10. Conclusion

Non-invasive respiratory support has revolutionized the management of respiratory distress in premature infants. CPAP remains the most studied and reliable option for early support, while HFNC and NIPPV provide alternatives with unique benefits. Continued innovation, global collaboration, and evidence-based practices are essential for improving survival and quality of life for the most vulnerable newborns.

## REFERENCES

1. Roehr CC, et al. Noninvasive Respiratory Support in Neonates. *Clin Perinatol*. 2021.
2. Roberts CT, Owen LS, Manley BJ. Nasal High-Flow Therapy for Newborns. *Paediatr Respir Rev*. 2020.
3. Sweet DG, et al. European Consensus Guidelines on the Management of Respiratory Distress Syndrome – 2022 Update. *Neonatology*.
4. Roehr CC, et al. Evidence Support and Guideline Recommendations for Noninvasive Respiratory Support in Neonates. *Clin Perinatol*. 2021.
5. DN Achilova, RA Amonov, LK Sharipova... - Annals of the Romanian Society for Cell Biology, 2021  
<https://scholar.google.com/scholar?oi=bibs&cluster=8449774988435725316&btnI=1&hl=ru>
6. Г Юлдашева, Б Рустамов - Международный журнал научной педиатрии, 2024  
<https://scholar.google.com/scholar?oi=bibs&cluster=14047001128517195322&btnI=1&hl=ru>
7. ГГ Юлдашева, ББ Рустамов, ДШ Ниёзова - Miasto Przyszłości, 2023  
<https://scholar.google.com/scholar?oi=bibs&cluster=3643167617656199069&btnI=1&hl=ru>
8. Rustamov Bakhtiyorjon. (2025). Surfactant Therapy in Premature Infants: A Critical Tool in Neonatal Care. *International Journal of Scientific Trends*, 3(4), 94–98. Retrieved from <https://scientifictrends.org/index.php/ijst/article/view/535>
9. Б.Б.Рустамов -Международный журнал научной педиатрии, 2022  
<https://scholar.google.com/scholar?oi=bibs&cluster=13779040844453027939&btnI=1&hl=ru>
10. Rasulova , S.H., Navruzova, S.I. и Muxamedova , S.T. 2024. Bolalarda allergiya va ta'sirlangan ichak sindromining differential tashhisi. *Журнал гуманитарных и естественных наук*. 1, 8 (апр. 2024), 184–188.  
<https://journals.tnmu.uz/index.php/gtfj/article/view/471>.

